Requests for Proposal

TB Alliance is a product development partnership (PDP), working to discover and develop better, faster acting, and affordable drugs to fight tuberculosis. We envision a world where no one dies of tuberculosis. However, this cannot be achieved without new, better, and faster-acting tuberculosis drug regimens. The Global Alliance for TB Drug Development (TB Alliance) was established in 2000 as a not-for-profit product development partnership to lead the search for new TB regimens and catalyze global efforts for new TB regimens that can bring hope, and health, to millions.

Launched in 2020, the LIFT-TB project aims to speed adoption and broad programmatic implementation of innovative 6-month MDR-TB treatments – BPaL/M. The project is co-funded by TB Alliance and KOICA, conceptualized and managed by TB Alliance, and implemented with the support of multiple global, regional, and country partners under the supervision of TB Alliance. TB Alliance is interested in comprehensively and systematically assessing the project’s impact and surface learnings.

• See the full RFP here.

The objective of this study is to gather insights into market feasibility, acceptability, pricing, implementation and policy considerations for a potential TBAJ-876-based pan-TB regimen for all forms of active TB and identifying regimen attributes to be kept in mind when designing a follow-on study to NC-009.

• See the full RFP here.

TB Alliance is requesting proposals from Contract Research Organizations (CROs) for services, pricing, and turnaround time related to ADMET/ PK studies for evaluation of novel chemicals for the potential use as anti-tuberculosis treatment.

• See the full RFP here.

TB Alliance is requesting proposals from Contract Research Organizations (CROs) for 5 dedicated full-time employees who would be synthesizing novel chemicals for potential use as anti-tuberculosis treatment.

• See the full RFP here.

TB Alliance is requesting proposals from firms to help advocate for TB-related research and development and health policy discussions with external stakeholders. The firm selected for engagement will work closely with TB Alliance staff to craft an advocacy plan of action encompassing US governmental and non-governmental stakeholders, as well as international entities relevant to this approach.

• See the full RFP here.

TB Alliance is requesting proposals from vendors to develop a results-based Monitoring and Evaluation (M&E) Plan of tuberculosis (TB) research and development (R&D) program. The selected vendor will coordinate with TB Alliance managers to develop and deliver a new M&E Framework that includes impact methodology and overarching results framework.

• See the full RFP here.

The objective of this RFP is to (a) conduct clinical and laboratory training needed to support BPaL/M implementation for relevant clinical and laboratory specialists at province and district level as aligned with the NTP, and (b) build awareness to garner support for BPaL/M implementation among province/district health offices/healthcare stakeholders. Proposals must cover work to be done in provinces together comprising 80-85% of MDR-TB burden presently, with a time frame of Q2-2024 to end of 2025., starting with the highest MDR-TB burden provinces.

• See the full RFP here.

The objective of this RFP is to (a) build capacity for implementation of BPaL/M at national (30 PMDT sites) and decentralized level (around 10 district level sites to inform scale-up in other decentralized sites), and (b) to engage the community and build awareness for community representatives at national and key district levels. The project will build upon work done so far, and be complementary to the GFTAM support in country. In context of decentralization, the project will be implemented in select high burden districts building upon the work done so far, as agreed with the NTP and the selected implementing partner.

• See the full RFP here.

The objective of this RFP is to (a) engage the community, build awareness and conduct training for community representatives at national and state levels, and (b) post such training, state level advocacy plans to be designed and implemented by the trained representatives. We expect proposals to include 5 states among the highest DR-TB burden states listed below.

• See the full RFP here.